Mixed Deck — All RAC Topics Flashcards

A medical device company plans to conduct a clinical study of a novel implantable cardiac defibrillator. The device is intended to sustain human life. According to 21 CFR 812, what is the regulatory status of this investigation and what is required before initiating the study?

Answer: Significant risk; both IRB approval and an approved Investigational Device Exemption (IDE) from the FDA are required.

An investigational device that is intended as an implant and presents a potential for serious risk, or is purported to be for use in supporting or sustaining human life, is considered a significant risk (SR) device. Clinical investigations of SR devices require both Institutional Review Board (IRB) approval and an approved Investigational Device Exemption (IDE) from the FDA before the study can begin.

In regulatory strategic planning, a 'target product profile' (TPP) serves as:

Answer: A prospective summary of the desired characteristics of a product that guides development decisions

The TPP is a prospective, dynamic document that articulates the intended clinical profile of the product and serves as a benchmark to align development and regulatory strategy.

Which section of a PMA application contains the results of all clinical investigations used to support device safety and effectiveness?

Answer: Section 6 – Clinical investigations

PMA Section 6 (Clinical Investigations) is where all clinical study data, protocols, and results must be reported.

An investigational device exemption (IDE) application is required before initiating a significant-risk device clinical study. Which FDA center reviews IDE applications for medical devices?

Answer: CDRH

The Center for Devices and Radiological Health (CDRH) reviews IDE applications for significant-risk medical device investigations.

A pharmaceutical company becomes aware of new data confirming a causal link between its marketed drug and a previously unknown serious adverse reaction. To update the Prescribing Information to add a new warning, which is the MOST appropriate regulatory submission to the FDA?

Answer: A "Changes Being Effected" (CBE-0) supplement.

For critical safety-related labeling changes, such as adding or strengthening a contraindication, warning, precaution, or adverse reaction, regulations permit the submission of a "Changes Being Effected" (CBE-0) supplement. This allows the applicant to implement the change immediately upon the FDA's receipt of the supplement, ensuring rapid communication of important safety information. A PAS would require FDA approval before implementation, causing a delay.

A pharmaceutical company is preparing a marketing application for a new chemical entity to be submitted in the US, EU, and Japan. Which document provides a harmonized structure for the quality, nonclinical, and clinical sections of the application, thereby streamlining the submission process across these regions?

Answer: Common Technical Document (CTD)

The Common Technical Document (CTD), developed by the International Council for Harmonisation (ICH), provides a standardized format for regulatory submissions in the ICH regions (US, EU, Japan). It is organized into five modules, with Modules 2 through 5 being common across regions, which significantly reduces the effort needed to compile applications for different regulatory authorities.

What is the primary purpose of an Annual Product Review (APR) in pharmaceutical manufacturing?

Answer: To assess consistency of existing processes and identify improvements

APRs evaluate the consistency of existing processes, quality of raw materials, and product quality to identify opportunities for improvement.

A regulatory affairs professional is reviewing a complaint that could qualify as an MDR-reportable event. Which criterion makes a malfunction MDR-reportable even without causing an injury?

Answer: The malfunction would likely cause or contribute to serious injury if it recurred

A malfunction is MDR-reportable if it would likely cause or contribute to serious injury or death if it were to recur.

Which ICH guideline provides recommendations on the content and format of Clinical Overview and Clinical Summary documents in the CTD?

Answer: ICH M4E (CTD for Registration of Pharmaceuticals — Efficacy)

ICH M4E specifically addresses the efficacy component of the Common Technical Document, including guidance on Clinical Overview and Clinical Summary content.

A manufacturer identifies a trend in field complaints suggesting a component is failing at an elevated rate. Under 21 CFR Part 820, the most appropriate initial response is to:

Answer: Initiate a CAPA investigation to determine root cause

§820.100 requires that quality data sources, including complaints, be analyzed to identify existing and potential causes of nonconforming products, triggering a CAPA investigation.

Under FDA's risk-based approach to device classification, a Class III device requires which type of premarket review?

Answer: Premarket Approval Application (PMA)

Class III devices, which support or sustain human life or present high risk, require a PMA demonstrating reasonable assurance of safety and effectiveness.

Which of the following activities is the BEST example of proactive post-market surveillance?

Answer: Conducting a customer survey to gather data on device usability and performance in a real-world setting.

Proactive post-market surveillance involves activities initiated by the manufacturer to actively search for information about a device's performance, rather than waiting for events to be reported. A customer survey is a method of actively seeking out this information. Investigating complaints, submitting vigilance reports, and issuing corrections are all reactive measures taken in response to an identified issue or event.

Under 21 CFR Part 820, labeling and packaging operations must include controls to prevent which specific risk?

Answer: Mislabeling and mix-ups during labeling operations

§820.120 requires procedures to prevent mislabeling and labeling mix-ups, including inspection of labeling for accuracy before distribution.

Which of the following BEST describes the role of the Qualified Investigator (QI) in Canada under ICH GCP?

Answer: The individual responsible for the conduct of a clinical trial at the trial site

In Canada, the Qualified Investigator is the site-level individual responsible for the conduct of the clinical trial, analogous to the Principal Investigator in the US.

A PMA applicant is required to submit a post-approval study. Where is this requirement typically documented?

Answer: In the PMA approval order conditions

Post-approval study requirements are specified as conditions in FDA's PMA approval order, binding the manufacturer to conduct the study.

In strategic regulatory planning, what does 'benefit-risk communication' primarily involve?

Answer: Transparently conveying the balance between a product's therapeutic benefits and its known risks to regulators and patients

Benefit-risk communication involves clearly presenting and contextualizing both the therapeutic benefits and the safety risks of a product to regulators, prescribers, and patients.

Under 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies), a Quality Assurance Unit (QAU) inspection of a study must be conducted:

Answer: At intervals adequate to ensure integrity, including at critical study phases

GLP requires the QAU to inspect each study at intervals adequate to ensure integrity of the study, with inspections at critical phases of the study being specifically required.

Which of the following best describes a Risk Evaluation and Mitigation Strategy (REMS)?

Answer: A program to ensure a drug's benefits outweigh its risks through specific safety measures

REMS are FDA-required programs for drugs with serious safety concerns that mandate specific interventions to ensure safe use.

Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?

Answer: Global regulatory harmonization strategy using ICH guidelines

A global harmonization strategy leveraging ICH guidelines enables concurrent submissions across regions by aligning data packages to shared standards.

A biotech company is developing a new biologic therapy for a serious, life-threatening disease with no current effective treatment. To potentially shorten the time to market, the company's regulatory strategy should prioritize:

Answer: Evaluating the criteria for one of the FDA's expedited programs, such as Breakthrough Therapy or Fast Track designation.

The FDA offers several expedited programs to facilitate and hasten the development and review of drugs and biologics that treat serious conditions and fill an unmet medical need. Programs like Fast Track and Breakthrough Therapy Designation are specifically designed for situations like the one described, offering benefits such as more frequent FDA meetings and the potential for accelerated approval and priority review. A key part of strategic planning is to determine if a product qualifies for any of these pathways.